Compare · Head-to-head
Larazotide vs Vasoactive Intestinal Peptide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Larazotide, then use the table to confirm fit.
Larazotide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Larazotide
Investigational oral peptide for gut-barrier integrity studied mainly in celiac disease.
01 · At a glance
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Primary fit | immune support research where you want a clear starting point | tissue repair & recovery and immune support comparisons |
| Evidence | Tier B | Tier C |
| Risk | low | medium |
| Experience level | intermediate | advanced |
| Budget tier | premium | premium |
| Administration route | oral | subcutaneous, intravenous |
02 · Use case & timing
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Goal fit | Immune Support | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Potential reduction in gluten-triggered gut-barrier disruption and GI symptom burden in celiac-focused trial settings. | Vasodilation, pulmonary vascular effects, and anti-inflammatory signaling in narrow research contexts. |
| Onset timeline | Barrier effects are expected quickly at the gut interface; symptom outcomes in studies are measured over days to weeks. | Hemodynamic effects occur within minutes; sustained protocols are needed for longer exposure. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Adverse effects | Clinical trials report good tolerability with adverse-event rates close to placebo. | Hypotension, flushing, tachycardia, headache, diarrhea, and infusion intolerance. |
| Contraindications | No clear formal contraindications identified, but evidence is limited outside celiac-disease research populations. | Avoid in hypotension, hypovolemia, or settings where strong vasodilation is unsafe. |
| Interaction notes | Minimal systemic absorption means drug-drug interaction risk appears low. | Likely additive with other blood-pressure-lowering or vasodilating agents. |
| Regulatory status | Investigational | Not approved |
| FDA flag | No current flag noted | FDA status unclear |
| WADA status | Not listed | Not listed |
04 · Age & monitoring
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | No reliable estimate yet |
| Estimated monthly cost | No reliable estimate yet | No reliable estimate yet |
| Cost confidence | No estimate | No estimate |
06 · Before you buy
| Decision factor | Larazotide | Vasoactive Intestinal Peptide |
|---|---|---|
| Tracked vendor listings | 0 listings | 0 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.